Related Experiment Videos
[New thrombocyte aggregation inhibitor in therapy of unstable angina]
1Kerckhoff Klinik-Herzzentrum Benekestrasse 2-8 61231 Bad Nauheim. christian.hamm@kerckhoff.med.uni-giessen.de
Insights
Glycoprotein IIb/IIIa antagonists significantly reduce cardiac events in unstable angina patients. These potent antiplatelet drugs, including abciximab, tirofiban, and eptifibatide, are crucial for managing this critical heart disease phase.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Unstable angina is a serious coronary heart disease complication.
- It carries a significant risk of myocardial infarction or death within 30 days.
Purpose of the Study:
- To evaluate the efficacy of Glycoprotein IIb/IIIa antagonists in treating unstable angina.
- To summarize findings from large randomized trials on these antiplatelet agents.
Main Methods:
- Review of several large randomized clinical trials.
- Analysis of data concerning Glycoprotein IIb/IIIa antagonists like abciximab, tirofiban, and eptifibatide.
- Assessment of outcomes in patients with and without percutaneous interventions.
Main Results:
- Glycoprotein IIb/IIIa antagonists reduced cardiac event rates by 10-70%.
- The beneficial effect was most pronounced in patients with elevated troponins.
- These drugs demonstrated effectiveness in both interventional and non-interventional settings.
Conclusions:
- Glycoprotein IIb/IIIa antagonists are highly effective in managing unstable angina.
- They represent a significant advancement in the treatment of patients with this condition.
- Their use is particularly beneficial for patients presenting with elevated troponin levels.
Abstract:
Unstable angina is a critical phase of coronary heart disease with a risk for myocardial infarction or death of up to 20% within 30 days. Glycoprotein IIb/IIIa antagonists are a new class of potent antiplatelet drugs. In several large randomized trials, it has been well established that the antibody abciximab, and the low molecular synthetic compounds tirofiban and eptifibatide, reduce the cardiac event rate by 10 to 70% in patients with and without percutaneous interventions. This effect was found to be predominately present in patients with elevated troponins. Accordingly, glycoprotein IIb/IIIa antagonists represent a major achievement for the treatment regimen of patients with unstable angina.